Radiotherapy for newly diagnosed primary central nervous system lymphoma: role and perspective - Sorbonne Université Accéder directement au contenu
Article Dans Une Revue Reports of Practical Oncology & Radiotherapy Année : 2023

Radiotherapy for newly diagnosed primary central nervous system lymphoma: role and perspective

Résumé

Whole brain radiotherapy (WBRT) has long been a key treatment of newly diagnosed primary central nervous system lym- phoma (PCNSL). In the 1990s, the addition of high dose Methotrexate-based induction chemotherapy (HD MTX-based CT) has enabled a drastic improvement in PCNSL patients outcome. However, combined treatment has led to radiation-induced delayed neurotoxicity, especially in older patients. Alternative treatment strategies have been assessed to improve the effi- cacy and neurotoxicity ratio. Nowadays, in the elderly patients WBRT is widely omitted or deferred, and in younger patients WBRT is challenged by high dose chemotherapy with autologous stem cell transplant (HCT-ASCT) for consolidation treat- ment after HD MTX-based CT. In this setting, this review is addressed to clinicians with the aim to summarize the role of WBRT in the treatment of newly diagnosed PCNSL and its perspectives.

Domaines

Cancer
Fichier principal
Vignette du fichier
95784-388643-1-PB.pdf (557.21 Ko) Télécharger le fichier
Origine Publication financée par une institution
Licence

Dates et versions

hal-04268581 , version 1 (02-11-2023)

Licence

Identifiants

Citer

Alice Thomas, Caroline Houillier, Delphine Antoni, Khe Hoang Xuan, Carole Soussain, et al.. Radiotherapy for newly diagnosed primary central nervous system lymphoma: role and perspective. Reports of Practical Oncology & Radiotherapy, 2023, 28 (2), pp.271-285. ⟨10.5603/RPOR.a2023.0028⟩. ⟨hal-04268581⟩
10 Consultations
15 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More